Longitudinal Adherence to Immunochemical Fecal Occult Blood Testing vs Guaiac-based FOBT in an Organized Colorectal Cancer Screening Program

被引:9
作者
Benito, Llucia [1 ,2 ]
Travier, Noemie [2 ,3 ]
Binefa, Gemma [2 ,3 ,4 ]
Vidal, Carmen [2 ,3 ]
Espinosa, Jose [2 ,3 ]
Mila, Nuria [2 ,3 ,4 ]
Garcia, Montse [2 ,3 ,4 ]
机构
[1] Univ Barcelona, Sch Nursing, Fundamental Care & Med Surg Nursing Dept, Hosp Llobregat, Barcelona, Spain
[2] Hosp Llobregat, Inst Biomed Res, IDI BELL, Barcelona, Spain
[3] Hosp Llobregat, Canc Prevent & Control Program, Catalan Inst Oncol, Barcelona, Spain
[4] Consortium Biomed Res Epidemiol & Publ Hlth CIBER, Madrid, Spain
关键词
RANDOMIZED CONTROLLED-TRIAL; 4; ROUNDS; CATALONIA; PARTICIPATION; PERFORMANCE; PILOT; SPAIN;
D O I
10.1158/1940-6207.CAPR-18-0091
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Longitudinal adherence is a critical component of the efficacy of stool-based screening programs because they should be repeated every 1-2 years. Few data have been published on the uptake in multiple rounds of fecal occult blood test-based (FOBT) colorectal cancer (CRC) screening. We calculated two measures of longitudinal adherence to biennial FOBT (guaiac fecal occult blood test:gFOBT or fecal immunochemical test: FIT) to better understand its impact on the programmatic effectiveness of a population-based CRC screening program (2000-2017). Ongoing population-based CRC program of men and women aged 50-69 years. Variables: Age at first CRC screening invitation, sex, number of screening invitations, number of screens, deprivation score, and uptake rate. Logistic regression models were used to assess the independent effect of sex, age at first invitation, deprivation, and the type of screening test offered on adherence. The uptake rate for guaiac fecal occult blood test (gFOBT) was 23.9%, and for the fecal immunochemical test (FIT), it was 37.4%. The overall rate of consistently screened invitees after seven rounds of screening was 14.2%, being 20.6% for those individuals who used FIT and 14.3% for those who used gFOBT. Factors associated with continued participation (consistent vs. inconsistent screenees) showed that the longitudinal adherence was associated with age, screening test used, and number of invitations. Continued participation was lower in individuals who were screened using FIT than among those screened using gFOBT [OR, 0.68; 95% confidence interval (CI), 0.57-0.81]. The overall rate of consistently screened invitees for colorectal cancer screening was higher with FIT than gFOBT. Studying the rate of individuals being current for screening may help to anticipate potential benefits before the long-term outcome data are available.
引用
收藏
页码:327 / 334
页数:8
相关论文
共 50 条
  • [31] Colorectal cancer screening using the faecal occult blood test (FOBt): a survey of GP attitudes and practices in the UK
    Damery, Sarah
    Clifford, Sue
    Wilson, Sue
    BMC FAMILY PRACTICE, 2010, 11
  • [32] Cost-effectiveness simulation and analysis of colorectal cancer screening in Hong Kong Chinese population: comparison amongst colonoscopy, guaiac and immunologic fecal occult blood testing
    Wong, Carlos K. H.
    Lam, Cindy L. K.
    Wan, Y. F.
    Fong, Daniel Y. T.
    BMC CANCER, 2015, 15
  • [33] Overall evaluation of an immunological latex agglutination system for fecal occult blood testing in the colorectal cancer screening program of Florence
    Rubeca, Tiziana
    Peruzzi, Benedetta
    Confortini, Massimo
    Rapi, Stefano
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2012, 27 (03) : 195 - 202
  • [34] A higher detection rate for colorectal cancer and advanced adenomatous polyp for screening with immunochemical fecal occult blood test than guaiac fecal occult blood test, despite lower compliance rate. a prospective, controlled, feasibility study
    Levi, Zohar
    Birkenfeld, Shlomo
    Vilkin, Alex
    Bar-Chana, Micha
    Lifshitz, Irena
    Chared, Miri
    Maoz, Eran
    Niv, Yaron
    INTERNATIONAL JOURNAL OF CANCER, 2011, 128 (10) : 2415 - 2424
  • [35] Immunochemical faecal occult blood testing to screen for colorectal cancer: can the screening interval be extended?
    Haug, Ulrike
    Grobbee, Esmee J.
    Lansdorp-Vogelaar, Iris
    Spaander, Manon C. W.
    Kuipers, Ernst J.
    GUT, 2017, 66 (07) : 1262 - 1267
  • [36] Colorectal Cancer Screening With Traditional and New-generation Fecal Immunochemical Tests: A Critical Review of Fecal Occult Blood Tests
    Meklin, Jannica
    Syrjanen, Kari
    Eskelinen, Matti
    ANTICANCER RESEARCH, 2020, 40 (02) : 575 - 581
  • [37] Population-based colorectal cancer screening: comparison of two fecal occult blood test
    Zubero, Miren B.
    Arana-Arri, Eunate
    Pijoan, Jose I.
    Portillo, Isabel
    Idigoras, Isabel
    Lopez-Urrutia, Antonio
    Samper, Ana
    Uranga, Begona
    Rodriguez, Carmen
    Bujanda, Luis
    FRONTIERS IN PHARMACOLOGY, 2014, 4
  • [38] Repeated screening for colorectal cancer with fecal occult blood test in Catalonia, Spain
    Garcia, Montse
    Maria Borras, Josep
    Binefa, Gemma
    Mila, Nuria
    Alfons Espinas, Josep
    Moreno, Victor
    EUROPEAN JOURNAL OF CANCER PREVENTION, 2012, 21 (01) : 42 - 45
  • [39] Quantitative immunochemical fecal occult blood test for neoplasia in colon cancer screening
    Yuan, Si Yi
    Wu, Wei
    Fu, Jing
    Lang, Yi Xuan
    Li, Ji Chi
    Guo, Ye
    Wang, Ya Nan
    Qian, Jia Ming
    Li, Jing Nan
    JOURNAL OF DIGESTIVE DISEASES, 2019, 20 (02) : 78 - 82
  • [40] A Systematic Review of Repeat Fecal Occult Blood Tests for Colorectal Cancer Screening
    Murphy, Caitlin C.
    Sen, Ahana
    Watson, Bianca
    Gupta, Samir
    Mayo, Helen
    Singal, Amit G.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2020, 29 (02) : 278 - 287